Telix Pharmaceuticals
61 hedge funds and large institutions have $36.6M invested in Telix Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 1 closing their positions.
2,300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 1
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
56% more funds holding
Funds holding: 39 → 61 (+22)
49% more capital invested
Capital invested by funds: $24.5M → $36.6M (+$12.1M)
0.18% more ownership
Funds ownership: 0.76% → 0.94% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.93M |
| 2 |
HWAM
Hennion & Walsh Asset Management
Parsippany,
New Jersey
|
+$1.53M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$1.25M |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$1.04M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$5.25M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$334K |
| 3 |
RBI
Raiffeisen Bank International
Vienna,
Austria
|
-$153K |
| 4 |
Mariner
Overland Park,
Kansas
|
-$64.8K |
| 5 |
Lazard Asset Management
New York
|
-$58.1K |
TLX Hedge Fund Activity: Q2 2026 in Review
61 of the 8,323 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q2 2026, worth a combined $36.6M — up 49% from $24.5M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TLX positions and 1 closed out — a net gain of 23 holders — while 21 added to existing stakes and 8 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $1.93M. The largest seller was Portolan Capital Management, cutting an estimated $5.25M.
- 61 institutional investors held Telix Pharmaceuticals (TLX) as of Q2 2026, up from 39 in Q1 2026.
- Funds reported $36.6M of Telix Pharmaceuticals stock for Q2 2026, up 49% quarter-over-quarter.
- 24 funds opened new Telix Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of +23 holders.
- The largest Telix Pharmaceuticals buyer in Q2 2026 was Marshall Wace, an estimated $1.93M added.
- The largest Telix Pharmaceuticals seller in Q2 2026 was Portolan Capital Management, an estimated $5.25M sold.
Based on aggregated 13F filings for Q2 2026.